OpenExamsFREE PRACTICE — ANY EXAM

Oklahoma Pharmacist — Requirements & Free Practice

US-OK · License preparation

600 free questions · Answer explanations · No signup required

Choose what to practice

Start with an exam below. Your examination requirements depend on your application pathway. View licensing requirements

Combined practice

Choose an exam or combined practice to begin.

Licenses, application pathways and examination requirements

Each license and applicant pathway has its own requirements and exemptions. Choosing practice questions does not determine your eligibility.

Pharmacist (Doctor of Pharmacy) License

License to engage in the practice of pharmacy in Oklahoma; the terms pharmacist, D.Ph. and Doctor of Pharmacy are interchangeable under 59 O.S. § 353.1.

Licensing authority: Oklahoma State Board of Pharmacy · Application information

Licensure by examination (NAPLEX) for graduates of a Board approved accredited school or college of pharmacy

All of the following:

Application
Oklahoma Application for Doctor of Pharmacy Certificate with the Board fee; the licensure process must be completed within one year (OAC 535:10-7-4(g)).
Education
Graduate of an accredited school or college of pharmacy approved by the Board (59 O.S. § 353.9(A)(1)); an official transcript with the degree date posted is required.
Experience
At least 1,500 hours of pharmacy practice training under a preceptor in a licensed pharmacy or approved training area (59 O.S. § 353.9(A)(2); OAC 535:10-5-1.3; OAC 535:10-7-5(a)).
Interview
Applicants may be required to appear before the Board for an in-person interview (OAC 535:10-7-4(d)).
Lawful Presence
Applicants must verify their lawful presence in the United States (Board General Requirements for Licensure).
Reexamination
After two failures of the licensure and/or jurisprudence examination the Board may require additional education; after three failures the Board may deny further examination (OAC 535:10-7-4(e)(1)-(2)).
Licensure by examination for foreign pharmacy graduates holding NABP FPGEC certification

All of the following:

Fpgec Certification
NABP FPGEC certification, which requires passing the FPGEE and the Test of English as a Foreign Language (TOEFL) (59 O.S. § 353.9(A)(1); OAC 535:10-7-2). The TOEFL is a language proficiency test and is a condition only.
Intern License
Obtain an Oklahoma intern license and complete 1,000 hours of internship in Oklahoma within 12 months of licensure as an Oklahoma intern (OAC 535:10-7-8(b)).
Interview
Applicants may be required to appear before the Board for interview (OAC 535:10-7-4(d)).
Lawful Presence
Applicant must be a U.S. citizen or national, a lawful permanent resident, or an alien authorized to work in the United States (Board Foreign Pharmacy Graduate Requirements for Licensure).
Licensure by reciprocity for foreign pharmacy graduates licensed in another state

All of the following:

Fpgec Certification
Successfully complete NABP FPGEC certification (FPGEE and TOEFL) (OAC 535:10-7-8(d)(1); OAC 535:10-7-2). The TOEFL is a language proficiency test and is a condition only.
Interview
In-person interview with the Board (Board General Requirements for Licensure, Reciprocity).
Reciprocity Requirements
Meet all reciprocity requirements of OAC 535:10-7-6, including an active original license by examination and one year of experience as an intern and/or pharmacist (OAC 535:10-7-8(d)(3)).
Licensure by reciprocity (NABP Electronic Licensure Transfer Program) for pharmacists licensed in another state

All of the following:

Application
NABP Official Application for Transfer of Pharmaceutical Licensure (e-LTP) and the Oklahoma fee (OAC 535:10-7-6(c)).
Experience
Minimum of one year of experience as an intern and/or pharmacist (OAC 535:10-7-6(b)).
Interview
In-person interview with the Board after passing the Oklahoma MPJE (Board General Requirements for Licensure, Reciprocity).
Military Expedited
Active-duty military personnel and spouses licensed as pharmacists in another state who receive orders for transfer or honorable discharge to Oklahoma are eligible for an expedited pharmacist reciprocity license, issued within 30 days of a complete application, with the fee waived for the first period of issuance (OAC 535:25-6-2); reciprocity is also expedited for qualifying military spouses (OAC 535:25-6-3(b)).
Original License
Applicant must reciprocate from an active, unrestricted original license obtained by examination in a participating state with like requirements (59 O.S. § 353.9(D); OAC 535:10-7-6(d)).
Prior Licensure Examination
OAC 535:10-7-4(e) names the NAPLEX among the licensure examinations every applicant must have passed; an original license obtained by a licensure examination that is no longer offered is prior evidence judged by the Board. For an original California license the NAPLEX must have been taken on or after January 1, 2004 (Board General Requirements for Licensure, Reciprocity).
Reinstatement of a pharmacist license cancelled at request or for failure to renew
Multistate Pharmacy Jurisprudence Examination (MPJE) — Oklahoma (practice unavailable)
Application
Written request and Board approved reinstatement application with fees; possible interview and any additional requirements the Board deems necessary (OAC 535:10-7-10(c)-(e),(g)).
Board Discretion Exam
The Oklahoma MPJE (the Board approved jurisprudence/law exam of OAC 535:10-7-4(e)) is required only when the Board so requires (OAC 535:10-7-10(f); 59 O.S. § 353.11(C)).
Continuing Education
Pay all back fees and prove all delinquent continuing education plus an additional 15 hours (59 O.S. § 353.11(C)).
Eligibility
Holder of a pharmacist certificate cancelled at request or for failure to renew; a revoked certificate, or a record already destroyed, is not eligible for reinstatement (OAC 535:10-7-10(a)).
Annual renewal of an Oklahoma pharmacist license
No examination is required for this applicant pathway.
Application
Renewal form and fee by the due date; late renewals incur the late fee (59 O.S. § 353.11(A); OAC 535:10-7-9(e)).
Continuing Education
At least 15 clock hours of accredited or Board-approved continuing professional education in the previous calendar year (59 O.S. § 353.11a(A)); a pharmacist who does not meet the CE requirement may obtain an inactive renewal certificate and may not practice in Oklahoma (59 O.S. § 353.11a(C)).
License
Hold a current Oklahoma pharmacist license in good standing (OAC 535:10-7-9(b)(1)).

Official no-examination sources

Effective from 2026-07-11.

Licensure by NAPLEX score transfer through NABP (original license by examination)

All of the following:

Education
Graduate of an accredited school or college of pharmacy approved by the Board; transcript with degree date required (59 O.S. § 353.9(E); OAC 535:10-7-2).
Experience
Same 1,500-hour internship requirement as licensure by examination (OAC 535:10-7-7(a); OAC 535:10-5).
Interview
Possible in-person interview with the Board (OAC 535:10-7-4(d)).
Military Fee Waiver
The Board waives the fee for active-duty military personnel and their spouses for the first period of issuance of a pharmacist score transfer license (OAC 535:25-6-2(e)).
Score Transfer
The applicant takes the NAPLEX for another jurisdiction and has NABP transfer the score to Oklahoma under the NABP Score Transfer program; the score transfer process must be completed within one year of passing the NAPLEX (OAC 535:10-7-7(b),(d)).

Foreign Pharmacy Graduate Equivalency Examination

Provider
National Association of Boards of Pharmacy
Format
Computerized fixed form
Exam questions
200 questions
Time limit
4.5 hours examination time; 5.5 hours total seat time
Passing score
Scaled score of 75
Examination outline
  • Foundational Biomedical Sciences (12%)
    • Anatomy and physiology
    • Biochemistry
    • Medical microbiology
    • Immunology
    • Pathophysiological bases of diseases
  • Pharmaceutical Sciences (31%)
    • Pharmaceutical calculations (eg, dose adjustments, delivery, ionization, ionic strength, isotonicity, ratio/percentage strength, osmolarity)
    • Medicinal chemistry
    • Medicinal chemistry: Physicochemical properties of drugs in relation to drug absorption, distribution, metabolism, and excretion (ADME)
    • Medicinal chemistry: Pathways of drug metabolism
    • Medicinal chemistry: Chemical bases for drug action, including bioorganic chemistry, structure-activity relationships, and fundamental pharmacophores related to drug-receptor interactions
    • Medicinal chemistry: Applicability to making drug therapy decisions
    • Pharmacology and toxicology
    • Pharmacology and toxicology: Pharmacodynamics, including drug-receptor interactions, agonists, antagonists, inverse agonists, and dose-response curves
    • Pharmacology and toxicology: Mechanisms of action of drugs, including biologics
    • Pharmacology and toxicology: Adverse effects and side effects of drugs
    • Pharmacology and toxicology: Mechanisms of drug interactions, including drug-drug, drug-disease, drug-food, drug-allergy, and drug-laboratory interactions
    • Pharmacology and toxicology: Mechanisms of acute and chronic toxic effects of xenobiotics, including drug and chemical overdose or exposure and antidotes
    • Pharmaceutics and biopharmaceutics
    • Pharmaceutics and biopharmaceutics: Dosage form development and drug delivery systems such as immediate release, sustained release, and controlled release
    • Pharmaceutics and biopharmaceutics: Disintegration and dissolution of solid oral dosage forms
    • Pharmaceutics and biopharmaceutics: Physicochemical properties of drugs, excipients, solutions, and dosage forms
    • Pharmaceutics and biopharmaceutics: Physical stability, chemical stability, and shelf-lives, including zero-, first-, second-, and pseudo-order reactions
    • Pharmaceutics and biopharmaceutics: Interactions between drug formulation and biological effects
    • Pharmaceutics and biopharmaceutics: Drug product manufacturing, including methods, processing, and quality assurance
    • Pharmacokinetics
    • Pharmacokinetics: Determining rates of absorption, distribution, metabolism, and excretion (ADME) of drugs
    • Pharmacokinetics: Factors affecting rates of ADME, including age, sex, genetics, diet, disease, and drug interactions
    • Pharmacokinetics: Biological half-lives of drugs and related dosing
    • Pharmacokinetics: Compartment models (one-, two-, and non-)
    • Pharmacokinetics: Linear and nonlinear pharmacokinetics
    • Pharmacokinetics: Principles of bioavailability, bioequivalence, and biosimilars
    • Pharmacogenomics (eg, population-based genetic influences on drug metabolism and efficacy, genetic testing, tumor genotyping, pharmacogenetic screening)
    • Extemporaneous compounding (eg, United States Pharmacopeia (USP) standards including Chapters <795>, <797>, and <800>; dosage form preparation calculations; techniques used to prepare and dispense sterile and nonsterile preparations)
  • Social, Behavioral, and Administrative Sciences (20%)
    • Pharmacy law and ethics
    • Pharmacy law and ethics: Laws and regulations governing pharmacy
    • Pharmacy law and ethics: Regulatory, oversight, and professional organizations
    • Pharmacy law and ethics: Principles and application of biomedical ethics
    • Health care systems
    • Health care systems: Organization, regulation, and financing of health care delivery in the United States
    • Health care systems: Factors that influence delivery and use of health care (eg, social, political, economic, and technological)
    • Pharmacoeconomics (eg, analysis, interpretation, application, humanistic outcomes)
    • Population-based care, pharmacoepidemiology, and public health
    • Population-based care, pharmacoepidemiology, and public health: Data sources and analytic tools
    • Population-based care, pharmacoepidemiology, and public health: Application of epidemiological study design
    • Population-based care, pharmacoepidemiology, and public health: Health promotion, disease prevention, and infection control
    • Population-based care, pharmacoepidemiology, and public health: Continuous quality improvement
    • Population-based care, pharmacoepidemiology, and public health: Social determinants and drivers of health
    • Practice management
    • Practice management: Financial management and budgeting
    • Practice management: Personnel management
    • Practice management: Business and strategic planning
    • Practice management: Risk management
    • Practice management: Procurement and inventory control
    • Professional communication
    • Professional communication: Verbal, nonverbal, written, and technology-based communication with patients, caregivers, providers, and stakeholders
    • Professional communication: Health literacy
    • Biostatistics and research methods (eg, study design, statistical tests, data collection instruments, research ethics)
    • Social and behavioral aspects of practice
    • Social and behavioral aspects of practice: Patient behavior including health-, illness-, and sick-role
    • Social and behavioral aspects of practice: Principles of behavior modification
    • Social and behavioral aspects of practice: Patient adherence
    • Social and behavioral aspects of practice: Cultural awareness
  • Pharmacy Practice and Clinical Sciences (37%)
    • Clinical pathophysiology as it applies to treatment of disease processes
    • Data collection (eg, patient history, physical assessments, laboratory values, point-of-care testing)
    • Data assessment (eg, clinical calculations, interpretation of data, diagnosing)
    • Patient-care decision making, therapy recommendations, and education (eg, plan, implement, monitor, follow-up)
    • Patient safety (eg, drug interactions, toxicity, drug-induced disease, drug use disorders)
    • Disease prevention (eg, screenings, immunization, non-pharmacological therapies, lifestyle modifications)
    • Personalized medicine (eg, pharmacokinetics, pharmacogenetics)
    • Evidence-based practice
    • Evidence-based practice: Practice guidelines
    • Evidence-based practice: Drug information and evaluation
    • Evidence-based practice: Information source reliability
    • Evidence-based practice: Clinical trial evaluation
    • Self-care, including using natural products
Examination sources

North American Pharmacist Licensure Examination

Provider
National Association of Boards of Pharmacy
Format
Computerized fixed form
Exam questions
225 questions
Time limit
6 hours
Passing score
Pass or Fail
Examination outline
  • Foundational Knowledge for Pharmacy Practice (25%)
    • Pharmaceutical science principles and concepts
    • Pharmaceutical science principles and concepts: Pharmacology
    • Pharmaceutical science principles and concepts: Pharmacokinetics, pharmacodynamics, or pharmacogenomics
    • Pharmaceutical science principles and concepts: Pharmaceutics
    • Pharmaceutical compounding
    • Pharmaceutical compounding: Nonsterile preparations
    • Pharmaceutical compounding: Sterile preparations
    • Pharmaceutical calculations
    • Pharmaceutical calculations: Patient parameters or laboratory measures
    • Pharmaceutical calculations: Quantities of drugs to be dispensed or administered
    • Pharmaceutical calculations: Rates of administration
    • Pharmaceutical calculations: Dose conversions
    • Pharmaceutical calculations: Drug concentrations, ratio strengths, osmolarity, or osmolality
    • Pharmaceutical calculations: Quantities of drugs or ingredients to be compounded
    • Pharmaceutical calculations: Nutritional needs and the content of nutrient sources
    • Pharmaceutical calculations: Biostatistical, epidemiological, or pharmacoeconomic measures
    • Pharmaceutical calculations: Pharmacokinetic parameters
    • Drug development processes (eg, clinical trial phases, emergency use authorizations)
    • Research design principles and biostatistics (eg, blinding, randomization, biases, statistical tests and outcomes, ethics)
    • Retrieval, assessment, and interpretation of primary, secondary, and tertiary resources
  • Medication Use Process (Prescribing, Transcribing and Documenting, Dispensing, Administering, and Monitoring) (25%)
    • Prescriptions and medication order interpretation
    • Prescriptions and medication order interpretation: Drug names and therapeutic classes
    • Prescriptions and medication order interpretation: Indications, usage, and dosing regimens
    • Prescriptions and medication order interpretation: Available dosage forms
    • Prescriptions and medication order interpretation: Prescription regulations (eg, boxed warnings, risk evaluation and mitigation strategies)
    • Prescriptions and medication order interpretation: Safety and effectiveness (eg, laboratory parameters, vital signs)
    • Therapeutic substitutions (eg, formulary restrictions, therapeutic alternatives, shortages, biosimilars)
    • Immunization services and documentation
    • Immunization services and documentation: Indications and scheduling
    • Immunization services and documentation: Contraindications and precautions
    • Immunization services and documentation: Storage and handling
    • Immunization services and documentation: Administration (eg, techniques, preparation, routes)
    • Immunization services and documentation: Adverse reactions
    • Medication handling, storage, stability, and disposal (eg, hazardous and nonhazardous drugs, controlled substances, parenteral medications, sharps handling, temperature control)
  • Person-Centered Assessment and Treatment Planning (40%)
    • Medication history, allergy history, and reconciliation
    • Health histories, screenings, and assessments
    • Patient health conditions, including special populations and medication-related factors
    • Patient health conditions, including special populations and medication-related factors: Signs, symptoms, and findings of medical conditions, etiology of diseases, or pathophysiology
    • Patient health conditions, including special populations and medication-related factors: Appropriateness of therapy (eg, medications, immunizations, non-drug therapy, dosing, contraindications, warnings, evidence-based decision making)
    • Patient health conditions, including special populations and medication-related factors: Interactions (eg, drug-drug, drug-condition, drug-food, drug-allergy, drug-laboratory)
    • Patient health conditions, including special populations and medication-related factors: Errors and omissions (eg, dosing, duplication, additional therapy needed, unnecessary therapy)
    • Patient health conditions, including special populations and medication-related factors: Adverse drug reactions
    • Patient health conditions, including special populations and medication-related factors: Toxicologic exposures and overdoses
    • Patient health conditions, including special populations and medication-related factors: Adherence
    • Therapeutic monitoring, plan development, evaluation, and modifications
    • Therapeutic monitoring, plan development, evaluation, and modifications: Therapeutic goals, clinical endpoints, and follow-up
    • Therapeutic monitoring, plan development, evaluation, and modifications: Safety
    • Therapeutic monitoring, plan development, evaluation, and modifications: Effectiveness
    • Patient education
    • Patient education: Lifestyle modifications and health maintenance
    • Patient education: Medication use, storage, and disposal
    • Patient education: Disease state management
    • Over-the-counter medications and dietary supplements
    • Devices to administer medications and self-monitoring tests
  • Professional Practice (5%)
    • Adverse drug event reporting and medication error reporting (eg, MedWatch, VAERS)
    • Public health initiatives and risk-prevention programs (eg, tobacco and nicotine cessation, antimicrobial stewardship, health screenings, opioid stewardship)
    • Social determinants and drivers of health
    • Ethical considerations (eg, informed consent, ethical principles, professional conduct and responsibility, patient confidentiality)
  • Pharmacy Management and Leadership (5%)
    • Pharmacy operations (eg, operational planning, risk management, regulations and regulatory bodies, technology applications and informatics, error-prevention strategies, medication safety)
    • Inventory and supply management (eg, drug recalls, drug shortages)
    • Quality improvement activities (eg, medication use evaluation, root-cause analysis, continuous quality improvement)
    • Mentorship and preceptorship (eg, providing and receiving feedback, delegation of work activities, preceptor roles)
Examination sources

Multistate Pharmacy Jurisprudence Examination (MPJE) — Oklahoma

Provider
National Association of Boards of Pharmacy; administered by Pearson VUE
Format
Computer adaptive, selected-response (multiple choice and multiple response)
Exam questions
120
Time limit
2.5 hours
Passing score
Reported as pass or fail; 5 attempts per jurisdiction
Exam fee
NABP: $100 non-refundable eligibility fee plus $170 purchase fee per jurisdiction
Examination outline
  • Area 1 — Licensure/Personnel (22%)
    • 1.1 – Responsibilities of the pharmacist and non-pharmacist personnel
    • 1.1 — Qualifications, scope of duties, limitations, and restrictions of duties, or conditions to practice for pharmacists-in-charge (or equivalent) and pharmacists
    • 1.1 — Qualifications, scope of duties, limitations, and restrictions of duties, or conditions to practice for non-pharmacist personnel
    • 1.2 – Licensures, registrations, and certifications for pharmacists or non-pharmacist personnel
    • 1.2 — Qualifications, examinations, internships, maintaining pharmacist competency, and renewals of licensures, registrations, or certifications
    • 1.2 — Classifications and processes of disciplinary actions
    • 1.2 — Reporting to and participating in programs addressing the inability to practice with reasonable skill and safety
  • Area 2 — Pharmacist Practice (33%)
    • 2.1 – Requirements for issuing prescriptions/drug orders
    • 2.1 — Requirements for drug uses, limitations, or restrictions
    • 2.1 — Scope of authority, scope of practice, limitations or restrictions of practice, and valid registration of practitioners who are authorized to prescribe, dispense, or administer drugs
    • 2.1 — Requirements for issuing non-controlled prescriptions/drug orders
    • 2.1 — Requirements for issuing controlled prescriptions/drug orders
    • 2.1 — Authority limitations of practitioners’ ability to authorize refills
    • 2.2 – Conditions under which the pharmacist or non-pharmacist personnel participates in the administration of drugs in the management of patients’ therapy
    • 2.3 – Requirements regarding counseling
    • 2.3 — Counseling or offering to counsel
    • 2.3 — Documenting counseling or documenting offering to counsel
    • 2.4 – Returning or reusing drugs
    • 2.5 – Regulations and agencies regarding pharmacy practice
    • 2.5 — Requirements for promoting quality and safety of public health
    • 2.5 — Protecting patient and health record confidentiality
  • Area 3 — Dispensing Requirements (24%)
    • 3.1 – Responsibilities for determining whether prescriptions/drug orders are issued for a legitimate medical purpose, and within all applicable restrictions
    • 3.2 – Transferring prescription/drug order information between pharmacies by authorized personnel
    • 3.3 – Prospective drug utilization reviews
    • 3.3 — Requirements for reporting to PMP and accessing PMP data
    • 3.4 – Exceptions to dispensing or refilling prescriptions/drug orders
    • 3.5 – Labeling of dispensed drugs
    • 3.6 – Packaging of dispensed drugs
    • 3.7 – Drug product conditions prohibiting dispensing
    • 3.8 – Requirements for the distribution and/or dispensing of non-prescription pharmaceutical products, including controlled substances and hazardous drugs
    • 3.8 — Dispensing or administration
    • 3.8 — Labeling of non-prescription drugs and devices
    • 3.8 — Packaging and repackaging of non-prescription drugs and behind-the-counter products
    • 3.8 — Dispensing-restricted, non-prescription drugs
  • Area 4 — Pharmacy Operations (21%)
    • 4.1 – Ordering, acquisition, and distribution of drugs, including maintenance and content of such records
    • 4.1 — Ordering and acquisition, including the maintenance and content of such records
    • 4.1 — Distribution, including the maintenance and content of such records
    • 4.2 – Recordkeeping in compliance with legal requirements, including content, inventory, maintenance, storage, handling, and reporting
    • 4.2 — Non-dispensing requirements for operations of pharmacies or practice settings
    • 4.2 — Possession, storage, and handling of non-hazardous drugs
    • 4.2 — Training, possession, handling, storage, and disposal of hazardous drugs
    • 4.2 — Allowing non-pharmacist personnel access to drugs
    • 4.2 — Requirements for conducting controlled substance inventories
    • 4.3 – Delivery of drugs
    • 4.4 – Conditions for permitted or mandated product selection
    • 4.5 – Compounding sterile, nonsterile, hazardous, and non-hazardous preparations
    • 4.6 – Centralized prescription processing or central-fill pharmacy dispensing
    • 4.7 – Requirements for the registration, licensure, certification, or permitting of a practice setting or business entity
    • 4.7 — Requirements for registration, license, certification, or permitting of a practice setting
    • 4.7 — Requirements for the renewal or reinstatement of a license, registration, certificate, or permit of a practice setting
    • 4.7 — Requirements for an inspection of a licensed, registered, certified, or permitted practice setting
    • 4.7 — Classifications and processes of disciplinary actions that may be taken against a registered, licensed, certified, or permitted practice setting
Examination sources